Anpheros Search · Treatment

Hydroxycarbamide

Also known as: Siklos · Xromi

General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).

In short

Hydroxycarbamide has an approved use for sickle-cell disorders. In the European Union, the product Siklos is indicated for the prevention of recurrent painful vaso-occlusive crises, including acute chest syndrome, in paediatric and adult patients suffering from symptomatic sickle-cell syndrome. Additionally, the product Xromi is indicated in the European Union for the prevention of vaso-occlusive complications of Sickle Cell Disease in patients over 9 months of age.

Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency. · Source: European Medicines Agency (EMA), Siklos — EPAR, 28/04/2026. © European Medicines Agency. · Source: European Medicines Agency (EMA), Xromi — EPAR, 28/04/2026. © European Medicines Agency.

AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.

Codes

RxNorm
5552 hydroxyurea
EMA
EMEA/H/C/000689, EMEA/H/C/004837

Official indications

Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.

EMA (EU) Siklos

Siklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in paediatric and adult patients suffering from symptomatic sickle-cell syndrome.

Source: European Medicines Agency (EMA), Siklos — EPAR, 28/04/2026. © European Medicines Agency.

Document date: 28/04/2026 · Official document →

EMA (EU) Xromi

Xromi is indicated for the prevention of vaso-occlusive complications of Sickle Cell Disease in patients over 9 months of age.

Source: European Medicines Agency (EMA), Xromi — EPAR, 28/04/2026. © European Medicines Agency.

Document date: 28/04/2026 · Official document →

Related terms in the cited sources

Has an official indication for

In alphabetical order.

Other treatments A–Z

What people report

Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.

How these counts are made →

External resources

Questions

What is Hydroxycarbamide approved for in the European Union?

Siklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in paediatric and adult patients suffering from symptomatic sickle-cell syndrome. (Source: European Medicines Agency (EMA), Siklos — EPAR, 28/04/2026. © European Medicines Agency.)

Sources and attribution

  • Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
  • Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
  • This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
  • Source: European Medicines Agency (EMA), Siklos — EPAR, 28/04/2026. © European Medicines Agency.
  • Source: European Medicines Agency (EMA), Xromi — EPAR, 28/04/2026. © European Medicines Agency.

Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →